Buy ABCL by May 31, 2028.

Alright degenerates, put down the weekly options for 5 minutes and hear me out. **AbCellera Biologics (ABCL)** — Canadian biotech, antibody discovery platform, and the company about to drop a Phase 2 readout that management literally called *"by far the most important data readout in 2026."* When management says that, you listen. **THE PLAY:** ABCL-635 is a treatment for postmenopausal vasomotor symptoms (hot flashes). \~$6B U.S. market. Phase 1 already showed: * ✅ No liver toxicity (huge, this kills most …